Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021372 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 17
- Study locations
NCT00021372 is a Phase 2 study of Lymphoma that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 25 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 2 states.
The verdict
NCT00021372, a Phase 2 study of Lymphoma, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and estramustine in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG estramustine phosphate sodium
Study Locations (17)
Pennsylvania
- Bon Secours-Holy Family Health System - Altoona
- Delaware County Memorial Hospital - Drexel Hill
- Pinnacle Health Hospitals - Harrisburg
- Conemaugh Memorial Hospital - Johnstown
- Saint Mary Regional Center - Langhorne
- North Penn Hospital - Lansdale
- Paoli Memorial Hospital - Paoli
- Fox Chase Cancer Center - Philadelphia
- Pottstown Memorial Regional Cancer Center - Pottstown
- Reading Hospital and Medical Center - Reading
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- Kimball Medical Center - Lakewood
- South Jersey Regional Cancer Center - Millville
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
- Riverview Medical Center - Booker Cancer Center - Red Bank
- Community Medical Center - Toms River
- St. Francis Medical Center - Trenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1996-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021372
The ClinicalTrials.gov registry entry for NCT00021372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00021372 reports 17 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00021372 about?
NCT00021372 is a clinical study titled "Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and estramustine in treating patients who have...
What is the current status of trial NCT00021372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1996-02. Estimated completion is 2006-09.
What conditions does trial NCT00021372 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00021372?
The interventions under investigation include: paclitaxel (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00021372?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021372 being conducted?
This trial has 17 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.